Sawai Pharmaceutical (4555.T), one of Japan's top makers of generic drugs, has bought almost five percent of Kyorin (4569.T) and wants to turn the mid-sized drugmaker into a wholly owned unit through a tender offer, the Nikkei reported. Report
Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product
Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.
